$76.00
Manufacturer: Italy
Degenerative-involutional brain psychoorganichni syndromes or secondary consequences of cerebrovascular insufficiency, that is, primary and secondary disorders of mental activity in the elderly, characterized by memory impairment, confusion, disorientation, reduced motivation and initiative, reduced ability to concentrate; changes in the emotional and behavioral sphere: emotional instability, irritability, indifference to the environment; pseudomelanholia in the elderly.
Description
Gliatilin Storage:
active substance: choline alfoscerate; 4 ml of solution contain choline alfoscerate 1000 mg;
Excipients: water for injections.
Gliatilin Dosage form.
Solution for injection.
Gliatilin Basic physical and chemical properties:
clear colorless solution.
Pharmacotherapeutic group.
Drugs that affect the nervous system. Parasympathomimetics. Choline alfoscerate. ATX code N07A X02.
Pharmacological properties.
Pharmacodynamics.
Gliatilin is a drug that belongs to the group of central cholinomimetics with a predominant effect on the central nervous system (CNS). Choline alfoscerate as a carrier of choline and a precursor agent of phosphatidylcholine has the potential to prevent and correct biochemical damage, which are of particular importance among the pathogenic factors of psychoorganic involution syndrome, ie may affect reduced cholinergic tone and altered phospholipid composition of nerve sheaths. The drug contains 40.5% of metabolically protected choline. Metabolic protection provides the release of choline in the brain. Gliatilin has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.
The mechanism of action is based on the fact that when choline enters the body, alfoscerate is broken down by enzymes into choline and glycerophosphate: choline is taught in the biosynthesis of acetylcholine – one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. Thus, Gliatilin improves the transmission of nerve impulses in cholinergic neurons; has a positive effect on the plasticity of neuronal membranes and the function of receptors. Gliatilin improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.
Pharmacokinetics.
On average, almost 88% of the administered dose of Gliatilin is absorbed. The drug accumulates mainly in the brain (45% of the drug concentration in the blood), lungs and liver. Elimination of the drug occurs mainly through the lungs in the form of carbon dioxide (CO2). Only 15% of the drug is excreted in urine and bile.
Clinical characteristics.
Indication.
Acute period of severe traumatic brain injury with a predominantly stem level of damage (disturbance of consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage).
Degenerative-involutional cerebral psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, ie primary and secondary mental disorders in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional sphere and the sphere of behavior: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.
Contraindication.
Known hypersensitivity to the drug or its components.
Patients with psychotic syndrome, with severe psychomotor agitation.
Pregnancy or breastfeeding.
Recent Reviews